Form 4: CRISPR CEO Kulkarni's RSU Vesting and Tax-Related Share Sale

CRISPR Therapeutics CEO Samarth Kulkarni reported the vesting of 19,250 restricted stock units and a subsequent non-discretionary sale of 9,798 shares to cover tax obligations.

Summary

• Samarth Kulkarni, CEO and Director of CRISPR Therapeutics AG (CRSP), reported transactions involving the company's common shares.
• On March 10, 2026, 19,250 common shares were acquired through the vesting of restricted stock units (RSUs).
• These RSUs are part of an award granted on March 10, 2023, for 77,000 common shares, vesting quarterly over four years.
• Following the vesting, on March 11, 2026, Kulkarni disposed of 9,798 common shares at a price of $52.8 per share.
• This disposition was a mandatory sale to cover tax withholding obligations related to the RSU vesting, not a discretionary trade.
• After these transactions, Kulkarni beneficially owns 235,558 common shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation and tax management rather than a discretionary investment decision or a signal about the company's future performance.

Positives

• The vesting of 19,250 restricted stock units represents earned compensation for the CEO, aligning executive incentives with shareholder value over time.

Negatives

• A disposition of 9,798 common shares, even if for tax purposes, reduces the CEO's direct ownership stake in the company.

Future Outlook

The filing indicates future vesting events for the remaining restricted stock units on March 10, 2027, as part of the original grant schedule.

Management Comments

• The sale of 9,798 shares was mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation in connection with the vesting of these restricted stock units and does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the vesting of restricted stock units and subsequent 'sell to cover' transactions for tax purposes, are common and routine events for executives receiving equity-based compensation in publicly traded companies, especially within the biotechnology sector where long-term incentives are prevalent.

Stakeholder Impact

• Shareholders: The transactions are routine and related to executive compensation, not indicating a change in company strategy or performance. The CEO's direct ownership slightly decreased due to the tax sale, but overall equity compensation continues to align interests.
• Employees: No direct impact mentioned.

Next Steps

• The final quarter of the restricted stock unit award is scheduled to vest on March 10, 2027.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Samarth Kulkarni, Biotechnology